ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-OR048

Canonical Wnt Inhibitors Ameliorate Cystogenesis in a Mouse Orthologue of Human ADPKD

Session Information

Category: Genetic Diseases of the Kidney

  • 801 Cystic Kidney Diseases

Authors

  • Li, Ao, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Xu, Yuchen, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Fan, Song, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Meng, Jialin, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Shen, Xufeng, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Ma, Dongyue, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Zhang, Li, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Zhang, Xiansheng, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Wu, Guanqing, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • Liang, Chaozhao, Anhui Province PKD Center, Institute/Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
Background

ADPKD is a heterogeneous disease which is caused by mutations in the PKD1 or PKD2 genes. Our previous study indicated that lack of Pkd2 causes elevated β-catenin signaling in mouse tissues and cells (Kim et al. JASN 2009;20:2556). However, it remains unclear if β-catenin signaling plays a role in PKD phenotypes and if Wnt inhibitor halts the cyst formation in the disease models.

Methods

In this study, we crossed a newly generated standardized ADPKD mouse model for Pkd2 (Vil-Cre;Pkd2f3/f3) (Li et al J. Cell Mol. Med. 2017) with Ctnnb1+/- mice to generate the mouse model that haploinsufficiency of Ctnnb1 (Vil-Cre;Pkd2f3/f3;Ctnnb1+/-). In addition, we also explored the effects of canonical Wnt signaling inhibitors (XAV939 and LGK974) on amelioration of disease phenotypes. XAV939-treated group and its solvent DMSO control group (n≥5/group) were intraperitoneally treated by 50 mg/kg/d and the same amount of DMSO from postnatal days 10 (P10) to 60 (P60); while LGK974-treated group and its solvent control group were intragastrically treated by 3mg/kg/d from postnatal days 30 (P30) to 90 (P90). The XAV939 and LGK974 treated animals were sacrificed at P65 and P95, respectively.

Results

Vil-Cre;Pkd2f3/f3 mice with Ctnnb1+/- allele and the mice treated with XAV939 or LGK974 exhibit significantly prolonged lifespan, decreased cyst index, kidney/body ratio and improved renal function (BUN and Cr). All treated mice also showed significantly decreased proliferation, but no change for apoptosis, in renal cyst-lining epithelial cells. Canonical Wnt signaling targeted genes, including Axin2, Ccnd1 and c-Myc, were also significantly downregulated in the treated ADPKD mouse kidney.

Conclusion

Our study provides clear evidence for the importance of β-catenin signaling in Pkd2-associated ADPKD phenotypes and develops new Wnt inhibitors XAV939 and LGK974, which affects at different targets of Wnt signaling, as a potential therapeutic modality for ADPKD that currently lacks effective therapy.

Funding

  • Government Support - Non-U.S.